Tuesday, November 17, 2026Tue, Nov 17 Updated

Mergers, acquisitions and startup deals, and what they mean.

vVardis Prices IPO at $18, Below Range, Slides 7% in NYSE Debut

Dental firm vVardis raised $175 million at $18 a share, under its $21 to $24 range, then fell 7% in its NYSE debut. What the deal and the business look like.

Close-up of dental chair and equipment in a clinical setting.
Photo: Fitusm Assefa / Pexels

Shares of vVardis, a Swiss company that makes treatments for early tooth decay, fell 7% in their first day of trading on the New York Stock Exchange on Friday. The company had already cut its price to get the deal done, selling 9.7 million shares at $18 each to raise $175 million, according to the New York Post.

That price sat well under the $21 to $24 per share range vVardis had marketed to investors. The Post reported that the stock opened at $14 and was later trading below $17, so the figures given for the first day do not line up neatly.

A priced-down offering in a nervous market

An initial public offering, or IPO, is when a private company first sells shares to the public. Before pricing, the company and its bankers tour investors in a “roadshow” and set a target range. Pricing below that range means buyers would not pay what the company first asked.

The Post tied the weak start to wider pressure on US listings. A selloff in technology stocks driven by artificial intelligence has weighed on the IPO market, along with uncertainty over AI regulation and data center spending after Democrats gained ground in the midterm elections.

Lukas Muehlbauer, an associate at IPO research firm IPOX, said the selloff made investors more price-sensitive. He also pointed to the company’s ongoing losses and its heavy dependence on a single customer, which he said likely made the original valuation “harder to justify during the roadshow.”

Readers curious about how a new stock gets its first price on the exchange can see how the NYSE opening auction for IPOs works.

What vVardis sells

Sisters Haley and Goly Abivardi, both Swiss dentists, founded vVardis in 2020. The company is based in Zug, Switzerland. Its products, sold under the Curodont brand, are meant to repair and reverse early tooth decay without drilling or injections.

Its main US product is Curodont Repair Fluoride Plus. Sales of that product rose 112% in the nine months ended Sept. 30, and it was available at more than 20,000 US dental practices as of June 30, according to the company’s filing.

What it means for shareholders and the IPO market

People who bought at the $18 offer price saw the stock trade lower on day one. The company still raised $175 million, though less than it would have at its original range.

The debut also tests how healthcare listings hold up while tech shares fall. Healthcare is often treated as a defensive sector because people keep needing its services. Swiss biotech Windward Bio began trading the same day as vVardis.

Muehlbauer said he expects the healthcare IPO window to stay open, but that investors now have more room to push back on valuations. He added that biotech companies with backing from a major drugmaker may have an easier time raising money.

He noted that all seven US IPOs in October came from drug developers, in a month that usually sees roughly twice as many deals across all sectors.

What to watch

For vVardis, the next markers are its trading in the days after the debut and the losses and customer concentration that Muehlbauer flagged. For the wider market, the question is whether other healthcare companies can price their offerings inside their marketed ranges while the tech selloff continues.

Source: New York Post